Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG) for immunology disorders. Its proprietary platform produces targeted, high-potency antibodies using genetically engineered transchromosomic cattle, enabling scalable, plasma-free manufacturing. The company focuses on autoimmune diseases like type 1 diabetes, aiming for disease-modifying therapies with improved safety, re-dosing potential, and addressing unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.